On Tuesday, Shares of Mondelez International Inc (NASDAQ:MDLZ), gained 0.85% to $42.93.
Mondelēz International, the world’s pre-eminent maker of chocolate, biscuits, gum and candy, opened a new $30 million state-of-the-art chocolate production line here to capitalize on growing demand in its European confectionery business. The investment is part of the company’s ongoing journey to create a global best-in-class integrated supply chain by transforming its manufacturing assets and processes to reduce costs and improve productivity.
“We strongly believe in the growth opportunities in Europe’s snacking market,” said Jurgen Leisse President Central Europe, Mondelēz International. “As Poland’s market leader in biscuits and chocolate, we know that maintaining our competitive advantage requires best-in-class manufacturing technology, such as the ‘Line of the Future’ introduced recently.”
Mondelez International, Inc., through its auxiliaries, manufactures and markets snack food and beverage products worldwide. The company offers biscuits, counting cookies, crackers, and salted snacks; chocolates, and gums and candies; powdered beverages and coffee; and cheese and grocery products.
Shares of Fifth Third Bancorp (NASDAQ:FITB), inclined 3.07% to $19.81, during its last trading session.
Fifth Third Bancorp, declared that Dan Poston, its executive vice president and chief strategy and administrative officer, is leaving the Bank to join Vantiv, Inc., as executive vice president, planned client relations. In his new role at Vantiv, of which Fifth Third is a noteworthy customer, Poston will manage the relationship with the Bank, among other duties. Dan’s last day with Fifth Third Bank will be Oct. 1.
“This is a terrific opportunity for Dan and Vantiv, and while we will miss Dan, we are happy that he will be working closely with Fifth Third in his new role,” said Greg D. Carmichael, who is president of Fifth Third Bancorp and is slated to become chief executive officer on Nov. 1. “I’m confident that Dan will assist Vantiv continue its record of being extremely well-managed and successful, which will benefit all of us.”
Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors.
Finally, Immunomedics, Inc. (NASDAQ:IMMU), ended its last trade with 8.37% gain, and closed at $2.33.
Immunomedics, Inc., declared that sacituzumab govitecan, the Company’s lead investigational antibody-drug conjugate (ADC), continues to produce durable responses in patients with metastatic lung cancer who had relapsed or were refractory to their last cancer therapy. At the time of this analysis, 57 patients with metastatic lung cancer (28 non-small-cell lung cancer (NSCLC) and 29 small-cell lung cancer (SCLC)) had been enrolled into this multicenter study at doses ranging from 8-18 mg/kg given on days 1 and 8 every 21 days. The median number of preceding lines of therapy in the NSCLC and SCLC patients was 3 and 2.5, respectively. Across all tumor types, 12 mg/kg was declared the maximal tolerated dose and 10 mg/kg declared the recommended Phase 2 dose. Accrual at 10 mg/kg continues.
Treatment response in lung cancer patients administered doses of <=12 mg/kg was assessed by computed tomography using the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1). In NSCLC, the most common type of lung cancer, 6 of 19 patients achieved an objective response (objective response rate = 32%). In SCLC, 6 of 20 patients achieved an objective response (objective response rate = 30%). In the 10 mg/kg cohorts, the objective response (partial response) rates in NSCLC and SCLC were 3/10 (30%) and 3/5 (60%), respectively.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
